BioSpace News Archive

Infusion Associates (IA), a leading provider of medically prescribed outpatient infusion therapy, today has completed their first Aduhelm (aducanumab-avwa) infusion for a patient at their Grandville , Michigan location.

Pfizer Inc. today announced that the U.S. Food and Drug Administration (FDA) approved the Biologics License Application (BLA) for COMIRNATY® (COVID-19 Vaccine, mRNA) to prevent COVID-19 in individuals 16 years of age and older.

Novian Health Inc., a clinical stage medical device company focused on the development of image-guided laser therapy for the focal destruction of malignant and benign breast tumors, announced the second closing of a private placement financing, with total cash proceeds to date of about $7.5 million.

xMD Diagnostics, Inc. has been awarded a National Science Foundation (NSF) Small Business Innovation Research (SBIR) grant for $256,000 to conduct research and development work to improve the reliability of coronavirus detection from patient samples.

AB Science SA (Euronext - FR0010557264 - AB) today announced that it has received the first authorization to resume patient enrollment in the confirmatory Phase 3 study of masitinib (AB19001) in amyotrophic lateral sclerosis (ALS).

LUNGevity Foundation is partnering with The Hamoui Foundation to offer a new lung cancer research award program.

Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced the appointment of Nisha Nanda, Ph.D., to its Board of Directors.

Cara Therapeutics (Nasdaq: CARA) and Vifor Pharma today announced that the U.S. Food and Drug Administration (FDA) has approved KORSUVA™ (difelikefalin) for injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis

Connect Biopharma Holdings Limited today announced Mr. Jiang Bian has joined the Company as General Counsel & Chief Compliance Officer, effective August 20, 2021.

Theravance Biopharma, Inc. (“Theravance Biopharma” or the “Company”) (NASDAQ: TBPH), today announced top-line results from its Phase 2b dose-finding induction study of izencitinib, an orally administered, gut-selective pan-Janus kinase (JAK) inhibitor in development for the treatment of ulcerative colitis.